Antiviral immune mechanism of Toll‑like receptor 4‑mediated human alveolar epithelial cells type Ⅱ

Wang,Dandan; Wang,Jie

doi:10.3892/etm.2020.8963

Antiviral immune mechanism of Toll‑like receptor 4‑mediated human alveolar epithelial cells type Ⅱ

Authors:
- Dandan Wang
- Jie Wang
View Affiliations

Affiliations: Department of Infectious Disease, Xuzhou Children's Hospital Affiliated to Xuzhou Medical University, Xuzhou, Jiangsu 221006, P.R. China
Published online on: June 30, 2020 https://doi.org/10.3892/etm.2020.8963
Pages: 2561-2568
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression of Toll‑like receptor (TLR)4 and its downstream substances, myeloid differentiation factor 88 (MyD88), NF‑κB p65, tumor necrosis factor‑α (TNF‑α) and GR in human alveolar epithelial cells type Ⅱ (AEC Ⅱ) infected with respiratory syncytial virus (RSV) were investigated, and the antiviral immune mechanism mediated by TLR4 was explored. Human AEC Ⅱ were divided into TLR4‑/‑ group, normal group and TLR4+ group, and also into control group, RSV group and RSV+MP (methylprednisolone) group. MTT assay was used to measure the survival of cells after TLR4 knockout and overexpression, and the survival of normal cells after treatment with MP. The concentration of TLR4, MyD88, NF‑κB p65, TNF‑α, and GR was measured by ELISA after TLR4 knockout and overexpression. Reverse transcription‑quantitative PCR (RT‑qPCR) was used to measure the mRNA expression of the gene knockout and overexpression groups. RT‑qPCR and western blot analysis were used to determine the expression of TLR4, MyD88, NF‑κB p65 and GR in RSV and RSV+MP groups. The concentration of the detected substances in the TLR4‑/‑ group was significantly lower than that in the normal group (P<0.01 and <0.001), and in the TLR4+ group was significantly higher than that in the normal group (P<0.05, <0.01 and <0.001); the expression of RSV in the TLR4‑/‑ group was significantly higher than that in the normal group (P<0.001), and in the TLR4+ group was significantly lower than that in the normal group (P<0.05). The expression levels of TLR4, MyD88 and NF‑κB p65 in the RSV and RSV+MP groups were significantly higher than those in the control group (P<0.05, <0.01 and <0.001), and the increase presented in the RSV+MP group was significantly lower than that in the RSV group (P<0.05 and <0.01). TLR4‑mediated antiviral immunity of human AEC Ⅱ can reduce the levels of TLR4, MyD88, NF‑κB p65 and TNF‑α and increase the level of GR, participating in the immune defense and reducing the damage of the viral epithelial cells of human type Ⅱ alveoli, thus improving human immunity.

View Figures

View References

1	Hofer CC, Woods PS and Davis IC: Infection of mice with influenza A/WSN/33 (H1N1) virus alters alveolar type Ⅱ cell phenotype. Am J Physiol Lung Cell Mol Physiol. 308:L628–L638. 2015.PubMed/NCBI View Article : Google Scholar
2	Liu Y, Kumar VS, Zhang W, Rehman J and Malik AB: Activation of type Ⅱ cells into regenerative stem cell antigen-1(+) cells during alveolar repair. Am J Respir Cell Mol Biol. 53:113–124. 2015.PubMed/NCBI View Article : Google Scholar
3	Schmiedl A, Kerber-Momot T, Munder A, Pabst R and Tschernig T: Bacterial distribution in lung parenchyma early after pulmonary infection with Pseudomonas aeruginosa. Cell Tissue Res. 342:67–73. 2010.PubMed/NCBI View Article : Google Scholar
4	Tumurkhuu G, Dagvadorj J, Jones HD, Chen S, Shimada K, Crother TR and Arditi M: Alternatively spliced myeloid differentiation protein-2 inhibits TLR4-mediated lung inflammation. J Immunol. 194:1686–1694. 2015.PubMed/NCBI View Article : Google Scholar
5	Hartshorn KL: Role of surfactant protein A and D (SP-A and SP-D) in human antiviral host defense. Front Biosci (Schol Ed). 2:527–546. 2010.PubMed/NCBI View Article : Google Scholar
6	Ariki S, Nishitani C and Kuroki Y: Diverse functions of pulmonary collectins in host defense of the lung. J Biomed Biotechnol. 2012(532071)2012.PubMed/NCBI View Article : Google Scholar
7	Beutler B: Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 430:257–263. 2004.PubMed/NCBI View Article : Google Scholar
8	Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K and Akira S: Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity. 11:443–451. 1999.PubMed/NCBI View Article : Google Scholar
9	Hoshino K, Tsutsui H, Kawai T, Takeda K, Nakanishi K, Takeda Y and Akira S: Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol. 162:5041–5044. 1999.PubMed/NCBI
10	Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM and Aderem A: The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 410:1099–1103. 2001.PubMed/NCBI View Article : Google Scholar
11	Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H and Bauer S: Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 303:1526–1529. 2004.PubMed/NCBI View Article : Google Scholar
12	Ricard JD, Dreyfuss D and Saumon G: Production of inflammatory cytokines in ventilator-induced lung injury: A reappraisal. Am J Respir Crit Care Med. 163:1176–1180. 2001.PubMed/NCBI View Article : Google Scholar
13	Kawai T, Takeuchi O, Fujita T, Inoue J, Mühlradt PF, Sato S, Hoshino K and Akira S: Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol. 167:5887–5894. 2001.PubMed/NCBI View Article : Google Scholar
14	Barton GM and Medzhitov R: Toll-like receptor signaling pathways. Science. 300:1524–1525. 2003.PubMed/NCBI View Article : Google Scholar
15	Cyr SL, Angers I, Guillot L, Stoica-Popescu I, Lussier M, Qureshi S, Burt DS and Ward BJ: TLR4 and MyD88 control protection and pulmonary granulocytic recruitment in a murine intranasal RSV immunization and challenge model. Vaccine. 27:421–430. 2009.PubMed/NCBI View Article : Google Scholar
16	Zhou B, Zhou H, Ling S, Guo D, Yan Y, Zhou F and Wu Y: Activation of PAR2 or/and TLR4 promotes SW620 cell proliferation and migration via phosphorylation of ERK1/2. Oncol Rep. 25:503–511. 2011.PubMed/NCBI View Article : Google Scholar
17	Yan ZQ: Regulation of TLR4 expression is a tale about tail. Arterioscler Thromb Vasc Biol. 26:2582–2584. 2006.PubMed/NCBI View Article : Google Scholar
18	Akira S and Takeda K: Toll-like receptor signalling. Nat Rev Immunol. 4:499–511. 2004.PubMed/NCBI View Article : Google Scholar
19	Gui J, Yue Y, Chen R, Xu W and Xiong S: A20 (TNFAIP3) alleviates CVB3-induced myocarditis via inhibiting NF-κB signaling. PLoS One. 7(e46515)2012.PubMed/NCBI View Article : Google Scholar
20	Janssen R, Pennings J, Hodemaekers H, Buisman A, van Oosten M, de Rond L, Oztürk K, Dormans J, Kimman T and Hoebee B: Host transcription profiles upon primary respiratory syncytial virus infection. J Virol. 81:5958–5967. 2007.PubMed/NCBI View Article : Google Scholar
21	Lizundia R, Sauter KS, Taylor G and Werling D: Host species- specific usage of the TLR4-LPS receptor complex. Innate Immun. 14:223–231. 2008.PubMed/NCBI View Article : Google Scholar
22	Baschant U and Tuckermann J: The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol. 120:69–75. 2010.PubMed/NCBI View Article : Google Scholar
23	Wei SD, Li JZ, Liu ZJ, Chen Q, Chen Y, Chen M and Gong JP: Dexamethasone attenuates lipopolysaccharide-induced liver injury by downregulating glucocorticoid-induced tumor necrosis factor receptor ligand in Kupffer cells. Hepatol Res. 41:989–999. 2011.PubMed/NCBI View Article : Google Scholar
24	Pizzi M: Sampling variation of the fifty percent end-point, determined by the Reed-Muench (Behrens) method. Hum Biol. 22:151–190. 1950.PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
26	Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, et al: Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 15:34–41. 2009.PubMed/NCBI View Article : Google Scholar
27	Caratti G, Matthews L, Poolman T and Kershaw S: Baxter MA and Ray D: Glucocorticoid receptor function in health and disease. Clin Endocrinol (Oxf). 4:185–193. 1997.
28	Oakley RH, Jewell CM, Yudt MR, Bofetiado DM and Cidlowski JA: The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J Biol Chem. 274:27857–27866. 1999.PubMed/NCBI View Article : Google Scholar
29	Zen M, Canova M, Campana C, Bettio S, Nalotto L, Rampudda M, Ramonda R, Iaccarino L and Doria A: The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev. 10:305–310. 2011.PubMed/NCBI View Article : Google Scholar
30	Kamiyama K, Matsuda N, Yamamoto S, Takano K, Takano Y, Yamazaki H, Kageyama S, Yokoo H, Nagata T, Hatakeyama N, et al: Modulation of glucocorticoid receptor expression, inflammation, and cell apoptosis in septic guinea pig lungs using methylprednisolone. Am J Physiol Lung Cell Mol Physiol. 295:L998–L1006. 2008.PubMed/NCBI View Article : Google Scholar
31	Bhattacharyya S, Brown DE, Brewer JA, Vogt SK and Muglia LJ: Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood. 109:4313–4319. 2007.PubMed/NCBI View Article : Google Scholar
32	Vollmer TR, Stockhausen A and Zhang JZ: Anti-inflammatory effects of mapracorat, a novel selective glucocorticoid receptor agonist, is partially mediated by MAP kinase phosphatase-1 (MKP-1). J Biol Chem. 287:35212–35221. 2012.PubMed/NCBI View Article : Google Scholar